Usual Adult Dose for Yellow Fever Prophylaxis

0.5 mL subcutaneously

• Booster doses may be given to patients vaccinated at least 10 years prior and at increased risk of yellow fever infection

Comments:

• A single dose provides long lasting protection in most healthy individuals, however an additional dose may be given who may not have an adequate or sustained vaccine response (e.g. vaccinated during pregnancy, hematopoietic stem cell transplant, HIV infected) who are at continued risk for exposure to yellow fever.

Usual Pediatric Dose for Yellow Fever Prophylaxis

9 months and older: 0.5 mL subcutaneously

• Booster doses may be given to patients vaccinated at least 10 years prior and at increased risk of yellow fever infection

Under 9 months: Contraindicated

Comments:

• Use in patients under 9 months old is contraindicated due to the risk of yellow fever vaccine-associated viscerotropic disease, which usually occurs 10 days after vaccination.
• A single dose provides long lasting protection in most healthy individuals, however an additional dose may be given who may not have an adequate or sustained vaccine response (e.g. vaccinated during pregnancy, hematopoietic stem cell transplant, HIV infected) who are at continued risk for exposure to yellow fever.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Desensitization:

• If immunization is imperative and the patient has a severe egg sensitivity and a positive skin test to the vaccine, the following may be used to administer the vaccine:

Administer the following successive doses subcutaneously at 15 to 20 minute intervals:
First: 0.05 mL of 1:10 dilution
Second: 0.05 mL of full strength
Third: 0.1 mL of full strength
Fourth: 0.15 mL of full strength
Fifth: 0.2 mL of full strength

• Perform desensitization only under direct supervision of a physician experienced in anaphylaxis management with necessary emergency equipment immediately available.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to any of the ingredients or eggs
• Age less than 9 months old
• Lactating women providing breast milk to infants less than 9 months of age
• Immunosuppressed patients

Safety and efficacy have not been established in patients younger than 9 months.

For further discussion on use of yellow fever vaccine during pregnancy and for documentation of a protective immune response to vaccine where it is deemed essential, contact the CDC at 1-970-221-6400.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Do not administer intravenously, intramuscularly, or intradermally.

Storage requirements:

• Refrigerate; do not freeze

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.